Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/4705
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYaren, Arzu-
dc.contributor.authorOztop, I.-
dc.contributor.authorKargi, A.-
dc.contributor.authorUlukus, C.-
dc.contributor.authorOnen, A.-
dc.contributor.authorSanli, A.-
dc.contributor.authorBinicier, O.-
dc.date.accessioned2019-08-16T11:36:27Z
dc.date.available2019-08-16T11:36:27Z
dc.date.issued2006-
dc.identifier.issn1368-5031-
dc.identifier.urihttps://hdl.handle.net/11499/4705-
dc.identifier.urihttps://doi.org/10.1111/j.1368-5031.2006.00742.x-
dc.description.abstractIn non-small-cell lung cancer (NSCLC), stage of the disease is still the most important prognostic factor. Other than stage, many biological markers and many other prognostic factors are studied to define their effects on prognosis of lung cancer. In this study, we aimed to evaluate the expressions of Bax and bcl-2 genes which are important in apoptosis and c-kit, which is a tyrosine kinase transmembrane receptor, as well as searched their response to treatment modalities and effects on survival. Sixty-nine NSCLC cases' pathological samples were stained with specific Bax, bcl-2 and c-kit dyes by immunohistochemical (IHC) methods. IHC evaluation was done by the semichantitative method according to the distribution and intensity of the staining. Twelve of 69 cases (17.4%) were stage I, 28 (40.5%) were stage II, 17 were (24.6%) stage IIIA, nine cases were (13.1%) stage IIIB and three cases (4.4%) were stage IV patients. Their histological subtypes were as follows: of 69 cases, 36 (52.2%) were squamous cell carcinoma, 28 (40.6%) were adenocarcinoma, five (7.2%) were adenosquamous cell carcinoma (two patients) and large-cell carcinoma (three patients). The positive immunostaining rates for Bax and bcl-2 in whole group, squamous cell carcinoma and adenocarcinoma groups were 40.6%/36.2%, 55.6/69.4% and 25.0/0.0%, respectively. The positive immune staining rates for c-kit in whole group, squamous cell carcinoma and adenocarcinoma groups were 7.2, 5.6 and 7.1%, respectively. We didn't find any correlation with Bax, bcl-2 and c-kit expressions and clinicopathological parameters such as age, tumour size, lymph node involvement, smoking, stage of the disease, response to radiotherapy and chemotherapy. Results are interpreted according to survival; bax and bcl-2 expressions were not so effective both in whole group and histologically subgrouped patients. C-kit expression was also found not related with survival in whole group whereas found as a bad prognostic factor in patients with squamous cell carcinoma. These findings could indicate that the expression of apoptotic pathway markers and c-kit may have a role in the prognosis of early stage NSCLC, especially with squamous cell carcinoma subtype. © Blackwell Publishing Ltd, 2006.en_US
dc.language.isoenen_US
dc.publisherBlackwell Publishing Ltden_US
dc.relation.ispartofInternational Journal of Clinical Practiceen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBaxen_US
dc.subjectbcl-2en_US
dc.subjectc-kiten_US
dc.subjectNSCLCen_US
dc.subjectPrognosisen_US
dc.subjectcisplatinen_US
dc.subjectgemcitabineen_US
dc.subjectprotein Baxen_US
dc.subjectprotein bcl 2en_US
dc.subjectstem cell factoren_US
dc.subjecttyrosine kinase receptoren_US
dc.subjectadulten_US
dc.subjectadvanced canceren_US
dc.subjectage distributionen_US
dc.subjectapoptosisen_US
dc.subjectarticleen_US
dc.subjectcancer sizeen_US
dc.subjectcancer stagingen_US
dc.subjectcancer survivalen_US
dc.subjectcigarette smokingen_US
dc.subjectclinical featureen_US
dc.subjectcontrolled studyen_US
dc.subjectcorrelation analysisen_US
dc.subjectfemaleen_US
dc.subjectgene expressionen_US
dc.subjecthistopathologyen_US
dc.subjecthumanen_US
dc.subjecthuman tissueen_US
dc.subjectlarge cell carcinomaen_US
dc.subjectlung adenocarcinomaen_US
dc.subjectlung non small cell canceren_US
dc.subjectlymph node metastasisen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectpriority journalen_US
dc.subjectprognosisen_US
dc.subjectsquamous cell carcinomaen_US
dc.subjectsurvival rateen_US
dc.subjectsurvival timeen_US
dc.subjecttreatment responseen_US
dc.titleBax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosisen_US
dc.typeArticleen_US
dc.identifier.volume60en_US
dc.identifier.issue6en_US
dc.identifier.startpage675
dc.identifier.startpage675en_US
dc.identifier.endpage682en_US
dc.identifier.doi10.1111/j.1368-5031.2006.00742.x-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.pmid16805752en_US
dc.identifier.scopus2-s2.0-33744508879en_US
dc.identifier.wosWOS:000238391400012en_US
dc.identifier.scopusqualityQ2-
dc.ownerPamukkale_University-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeArticle-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

33
checked on Nov 16, 2024

WEB OF SCIENCETM
Citations

27
checked on Nov 16, 2024

Page view(s)

58
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.